

Pregnancy Form

Protocol SPIRIT 2 EudraCT number: 2007-006185-15		ID Site N	ID Site No.		CASE NUMBER			
		Subje Subje	ct No. ct's initials		Trial Dru Imatinik or Dasatin	(Glee		
CLINICAL TRIAL BRE	SNANCY EC	DM					Pa	go 1 of 3
CLINICAL TRIAL PREGNANCY FORM 1. Country: UK 2. LOCAL CASE ID:								
I.				IFORMATION				
3. DATE OF BIRTH day month year 4. AGE yrs./mo.		5. RAG			6. HEIGHT	Cm	7. WEIGHT	r kg
Date of Last Menstrual Per	riod day	/ month	year	9. Expected Date	of Delivery	day	month	year
10. Method of Contraception 11. Contraception used as instructed yes no uncertain								
II.			HIS	TORY				
or occupational exposure t								
13. PREVIOUS OBSTETRIC HISTORY – provide details on all previous pregnancies below, including abortion or stillbirth (use page 3 if needed)								
			any abnormali	ties				
1								
3								
4								
14. DRUG INFORMATION -	- please list SPIR	IT 2 Study D	rugs first and a	I other therapies taker	n prior to or durin	ng pregna	ancy	
		Route	Treatment Dates		Indication		(specify week of pregnancy) Start Stop	
	<u> </u>	PLEASE F	AX FORM 1	O 0191 376 0748	3			



Pregnancy Form

Protocol SPIRIT (AGB14)		ID Site No.		CASE NUMBER				
EudraCT number: 2007-006185-15		Subject No.		Trial Drugs				
		Subject's initials		Imatinib (Gleevec) or				
				Dasatinib (Sprycel)				
	NICAL TRIAL PREGNANCY FORM	Л		Page 2 of 3				
	CAL CASE ID:							
	III. PREGNANCY INFORMATION							
18.	18. PRENATAL Have any specific tests, e.g. amniocentesis, ultrasound, maternal serum AFP, been performed during the pregnancy so far? No Yes Not known If yes, please specify test date and results:							
19.								
	Delivery							
	☐ Normal☐ Forceps/Ventouse☐ Caesarean sectionMaternal complications or problems related to birth:							
	Abortion							
	☐ Therapeutic ☐ Planned ☐ Spontaneous Please, specify reason and any abnormalities (if known)							
	Date of abortion/delivery day mo	onth year						
20.	MATERNAL PREGNANCY ASSOCIATED EVE	ENTS:						
	If the mother experiences a serious adverse ev	vent (SAE) during a pre	gnancy, please complete	an SAE form and submit as requested				
IV.		CHILD INF	ORMATION					
21.	Neonate ☐ Normal ☐ Abnormal ☐ St	tillhirth please specify	any abnormalities with da	ates:				
	Sex Height	Weight	Apgar Scores	Head circumference				
	☐ Male		1 min. 5 mins.					
	Female cm	kg	10 mins.	cm				
	For additional information, please use page 3 (please provide copies of	of relevant documentation)				
V.		SSESSMENT OF PR	REGNANCY OUTCOM	E				
22.	SERIOUSNESS CRITERIA Non Serious day month yea	ar		day month year				
	Mother died Stillbirth / Neonate died							
	Involved or prolonged inpatient hospitalisation Life-threatening							
Results in persistent or significant disability/incapacity Other Seriousness Criteria: Congenital anomaly/birth defect Other significant medical events								
23. ASSESSMENT OF CAUSALITY Please indicate the relationship between pregnancy outcome and investigational drug								
	Dasatinib (Sprycel) Not suspected Suspected							
	Imatinib (Gleevec)							
Not suspected Suspected								
	INFORMATION SOURCE							
24. NA	AME, ADDRESS AND TELEPHONE NUMBER O	OF INVESTIGATOR	25. REPORTING DATE EVENT	BY INVESTIGATOR/PERSON REPORTING				
				day month year				

PLEASE FAX FORM TO 0191 376 0748



Pregnancy Form

Protocol SPIRIT (AGB14)	ID Site No.		CASE NUMBER			
EudraCT number:	Subject No.		Trial Drugs Imatinib (Gleevec)			
2007-006185-15	Subject's initials		or			
			Dasatinib (Sprycel)			
CLINICAL TRIAL PREGNANCY FOR	RM		Page 3 of 3			
2. LOCAL CASE ID:						
FOR ADDITIONAL INFORMATION:						
INFORMATION SOURCE						
32. NAME, ADDRESS AND TELEPHONE NUMBER	R OF INVESTIGATOR	32. REPORTING DATE EVENT	BY INVESTIGATOR/PERSON REPORTING			
Cimpature			day month year			
Signature:						
Ы	EASE EAY FORM T	O 0191 376 07/8				